CN Patent

CN103298466A — 茶碱和非布索坦的联合治疗方法

Assigned to Takeda Pharmaceuticals USA Inc · Expires 2013-09-11 · 13y expired

What this patent protects

本发明涉及一种治疗还患有需要茶碱治疗的第二疾病状态的患者中高尿酸血症的方法，其中所述患者接受黄嘌呤氧化还原酶抑制剂和茶碱的联合治疗而不会导致对患者产生茶碱毒性以及不显著调整茶碱的制造商推荐剂量。

USPTO Abstract

本发明涉及一种治疗还患有需要茶碱治疗的第二疾病状态的患者中高尿酸血症的方法，其中所述患者接受黄嘌呤氧化还原酶抑制剂和茶碱的联合治疗而不会导致对患者产生茶碱毒性以及不显著调整茶碱的制造商推荐剂量。

Drugs covered by this patent

Patent Metadata

Patent number
CN103298466A
Jurisdiction
CN
Classification
—
Expires
2013-09-11
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.